Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
105.8 USD | -0.11% | -1.62% | -3.89% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.89% | 184B | |
-1.09% | 107B | |
-3.60% | 69.44B | |
+3.44% | 50.37B | |
+8.40% | 44.82B | |
+3.40% | 41.53B | |
+2.79% | 26.84B | |
+4.10% | 26.73B | |
+15.23% | 25.71B | |
-0.90% | 24.34B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Wells Fargo Raises Price Target on Abbott Laboratories to $121 From $116, Maintains Overweight Rating